GlobalData on MSN14d
Boehringer Ingelheim announces Phase III schizophrenia failuresThe company has said that all three of its CONNEX trials failed to meet expectations showing no significant impact on the ...
Boehringer Ingelheim’s trio of late-stage schizophrenia failures on Thursday came a day after the Department of Health and Human Services hit back on the pharma’s legal challenge to the IRA’s drug ...
GlobalData on MSN6mon
Boehringer Ingelheim acquires Nerio Therapeutics for $1.3bnBoehringer Ingelheim has acquired drug discovery and ... financial backing from a syndicate that includes the Bregua ...
HHS told the Second Circuit that Boehringer Ingelheim’s voluntary participation in Medicare negotiations “undermines” its ...
Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with ...
Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...
© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...
Lonza’s subsidiary Synaffix has secured licensing agreements with Boehringer Ingelheim and Mitsubishi Tanabe Pharma to advance antibody-drug conjugate (ADC) programmes, marking its continued ...
Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activity against the symptoms of ...
The heritage of Boehringer Ingelheim in developing medicines for respiratory diseases spans almost 100 years. Within the respiratory disease area, innovative treatments for chronic obstructive ...
Member of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim. “In the near future more can be expected. Our gratitude goes to the patients and clinical ...
Member of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim. “In the near future more can be expected. Our gratitude goes to the patients and clinical investigators ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results